Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

Tomer M. Mark, Isaac A. Bowman, Adriana C. Rossi, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N. Pearse, Faiza Zafar, Karen Pekle, David Jayabalan, Scott Ely, Morton Coleman, Selina Chen-Kiang, Ruben Niesvizky

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

We studied T-BiRD (thalidomide [Thalomid®], clarithromycin [Biaxin®], lenalidomide [Revlimid®] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov identifier: NCT00538733

Original languageEnglish (US)
Pages (from-to)2842-2849
Number of pages8
JournalLeukemia and Lymphoma
Volume55
Issue number12
DOIs
StatePublished - Dec 1 2014

Keywords

  • Clarithromycin
  • Dexamethasone
  • Lenalidomide
  • Newly diagnosed multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Mark, T. M., Bowman, I. A., Rossi, A. C., Shah, M., Rodriguez, M., Quinn, R., Pearse, R. N., Zafar, F., Pekle, K., Jayabalan, D., Ely, S., Coleman, M., Chen-Kiang, S., & Niesvizky, R. (2014). Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia and Lymphoma, 55(12), 2842-2849. https://doi.org/10.3109/10428194.2014.896005